| Compositions and methods for treating cancer -> Monitor Keywords |
|
|
 
Compositions and methods for treating cancerRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Carbohydrate (i.e., Saccharide Radical Containing) DoaiCompositions and methods for treating cancer description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060142207, Compositions and methods for treating cancer. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application claims priority to U.S. provisional patent application Ser. No. 60/429,287, filed 29 Mar. 2002, incorporated herein by reference. BACKGROUND OF THE INVENTION [0002] The term "cancer" generally refers to any of a group of more than 100 diseases caused by the uncontrolled growth of abnormal cells. Cancer can take the form of solid tumors and lymphomas, and non-solid cancers such as leukemia. Unlike normal cells, which reproduce until maturation and then only as necessary to replace wounded cells, cancer cells can grow and divide endlessly, crowding out nearby cells and eventually spreading to other parts of the body. [0003] The principal problem of cancer chemotherapy is achieving good therapeutic indices for the compounds administered to kill the tumor cells. In general, drugs and radiation used to kill cancer cells are also toxic to cells of normal tissue, and so side effects are often severe. The majority of drug-mediated cancer therapies rely on drugs that selectively poison dividing cells. These drugs can be effective, because cancer cells generally divide more frequently than normal cells. Unfortunately, however, there are exceptions to this rule in most cancers, which means that such drugs almost inevitably are unable to kill all cells in a tumor. Moreover, even for drugs that act on mechanisms specific to cancer cells, there are, in the majority of patients, cancer cells not killed by administration of the drug. [0004] While specific proteins can confer drug resistance to a cancer cell, such as the proteins responsible for the multiple drug resistance ("MDR") phenotype, the very nature of the tumor formed by solid cancers, particularly its vascular architecture, contributes significantly to the ability of the cancer to survive drug therapy. As a tumor grows, it requires a blood supply and the growth of new vasculature. The new vasculature that supports the tumor growth is, not surprisingly given the uncontrolled growth that characterizes most cancers, highly disordered, leaving significant portions of the tumor under-vascularized, and the vascularized portions of the tumor subject to intermittent blockage. Because the vasculature delivers oxygen (and chemotherapeutic agents) to cells, tumors therefore typically contain "hypoxic" regions, regions in which the oxygen concentration is significantly lower than in the vast majority of normal tissues and where there may be poor delivery of chemotherapeutic agents. [0005] Oxygen is critical in the supply of energy to a cell in the form of ATP produced by mitochondrial action. A cell's only other source of ATP in the amounts needed to support the cell is from anaerobic glycolysis. Given the demand for ATP in cell division and the hypoxic nature of tumors, it is therefore not surprising that many cancers exhibit, relative to normal cells, increased glycolysis. This attribute of cancer cells was described in the reference Dickens, 1943, Cancer Research 3:73, which reported "the typical intact cancer cell exhibits an unusual ability to utilize glucose by the process of anaerobic glycolysis through lactate". [0006] Given the increased glycolysis in cancer cells relative to normal cells, scientists questioned whether inhibition of anaerobic glycolysis by metabolic poisons would preferentially target cancer cells. The compound 2-deoxy-D-glucose (also known and referred to herein as 2-deoxyglucose and 2-DG) is such a metabolic poison. 2-DG inhibits glycolysis in cancer cells, as reported in the reference Woodward, 1954, Cancer Res. 14:599-605. However, while many cell-based and animal studies of 2-DG as an anti-cancer agent have been conducted, both as a single agent and in combination with other anti-cancer drugs and/or radiation, the compound has not been approved by any regulatory agency for use in the treatment of cancer. See Yamada, 1999, Cancer Chemother. Pharmacol. 44(1):59-64; Reinhold, September 2000, Oncol. Rep., 7(5):1093-97; Mese, March 2001, Anticancer Res. 21:1029-33; Lampidis, 2 Mar. 2001, PCT WO 01/82926, Yeung, 11 Dec. 2001, PCT WO 02/58741; and Pitha, 21 Mar. 2002, U.S patent publication No. 20020035071. [0007] There could be a significant therapeutic benefit from cytotoxic compounds that preferentially target cancer cells based on increased glycolysis. Because cancer cells are known to have, relative to normal cells, increased production of glucose transporters, including GLUT1 and GLUT3, one could attempt to target glucose transport in cancer chemotherapy. While a number of known anti-cancer agents have a structure that can be described as a glucose moiety attached to a cytotoxic agent, and so might be substrates for GLUT1 and/or GLUT3, none of these agents has been widely used with great success to treat cancer. [0008] One such compound, the naturally occurring compound streptozotocin [2-deoxy-2-(3-methyl-3-nitroso-ureido)-D-glucose] is an antibiotic and anti-mitotic compound produced by Streptomyces achromogenes (see also U.S. Pat. No. 3,694,428). In streptozotocin, a cytotoxic N-nitroso urea group is attached to the 2 position of glucosamine. The compound is relatively unstable in that the cytotoxic moiety is readily released from the compound in the presence of water. The compound appears to be transported into cells by the glucose transporter GLUT2, which may account for its toxicity to pancreatic islet cells. A limited number of streptozotocin analogs have also been prepared (see U.S. Pat. No. 3,940,383). However, neither streptozotocin nor its analogs has found any significant use in anti-cancer therapies. [0009] Glufosfamide (beta-D-glucosyl-ifosfamide mustard) is another anti-cancer agent that can be described as a cytotoxic agent linked to a glucose moiety. This compound contains the cytotoxic agent ifosfamide coupled to glucose via an ester linkage at the oxygen atom at the 1-position of glucose (see U.S. Pat. No. 5,622,936). The compound has been described as having been made in an effort to target the tumor's need for energy as a means to enhance uptake of ifosfamide into cancer cells (see the website of the dkfz, 14 Jan. 2003, www.toxea.de). The compound has been reported to be subject to cell surface glucose transport, via the SAAT1 receptor. Like streptozotocin, however, glufosfamide is relatively unstable, both chemically and enzymatically, ensuring that ifosfamide will be cleaved from the glucose after administration. Such cleavage could take place in the plasma, by the action of serum esterases, or in the cell, allowing the ifosfamide potentially to diffuse from the cell, which in either event could lead to increased toxicity and/or decreased efficacy. [0010] The glyco-S-nitrosothiols are likewise relatively unstable compounds that can be described as cytotoxic agents linked to sugars. These compounds have been described as targeting tumor cells that over-express GLUT1 preferentially (see Ramirez et al., 1996, Bioorg. Med. Chem. Lett. 6(21): 2575-2580; and Cantuaria et al., 15 Jan. 2000, Cancer 88(2): 381-388). One glyco-S-nitrosothiol called 2gluSNAP has a structure in which a nitric oxide donating cytotoxic moiety (S-nitroso-N-acetyl-penicillamine) is linked to 2-deoxyglucosamine at the 2 position via an amide bond. The resulting compound is unstable, which can result in release of the cytotoxic nitric oxide before entry into the targeted cell or diffusion out of the targeted cell. [0011] Compounds characterized as single photon-emitting radiotracers that contain a glucose moiety linked to a single photon-emitting moiety via a heterocyclic, hydrocarbon, or aromatic group have been described as allegedly useful for the diagnosis and treatment of cancer (see PCT publication No. WO 99/20316). These compounds include, for example, 2-O-(3'-iodobenzyl)-D-glucose and N-(4'-iodobenzyl)-D-glucosamine. [0012] Compounds characterized as prodrug forms of pharmacologically active substances, including anti-cancer agents, and that contain a glucose or other sugar moiety linked to a pharmacologically active agent at the 1 position either directly or through a self-immolative spacer have been described (see U.S. Pat. No. 5,621,002) as substrates for human glycosidases without indication of whether the glucose moiety contributed to the specificity of the prodrug for a cancer cell. [0013] Thus, while compounds have been made that contain a cytotoxic agent linked to glucose, most of those compounds have not been approved for the treatment of cancer, and none of those compounds appears to have significant specificity for cancer cells. There remains a need for methods and compositions for treating cancer, including tumors, non-solid cancers, and cancer cells, that are widely applicable in a variety of cancers. The present invention provides such methods, as well as compounds and compositions useful in those methods. SUMMARY OF THE INVENTION [0014] The present invention provides methods for treating cancer and pre-cancerous cells and tissues, as well as compounds that are conjugates of glucose or an analog or derivative thereof and an anti-cancer agent and compositions for use in the methods of the invention. [0015] In one aspect, the present invention provides methods for treating cancer in a subject, comprising administering to the subject an effective amount of a non-releasable glucose-anti-neoplastic agent conjugate, wherein the glucose portion is a glucose or a derivative or analog thereof, such as 2-deoxyglucose. [0016] In one group of embodiments, the glucose-anti-neoplastic agent conjugate has the formula: Glc-L-Z, wherein Glc is glucose, 2-deoxyglucose, or a 2-deoxyglucose derivative; L is a non-releasable linkage; and Z is an anti-neoplastic agent. Preferred linkages between Glc and L include either an ether or a carbamate linker to the oxygen at the 2 position of glucose and either an alkyl amine, amide, carbamate, urea, or sulfonamide linkage to the nitrogen at the 2 position of glucosamine. Preferred 2-deoxyglucoses and derivatives are D-(+)-2-deoxyglucose and D-(+)-2-amino-2-deoxyglucose. The above method can also be carried out as part of a combination therapy method wherein at least one additional anti-neoplastic agent is administered to the subject either before, during, or after administration of the glucose-anti-neoplastic agent conjugate. [0017] The methods of the invention find broad applicability to the treatment of a number of cancers, due in large part to their ability to treat cancer at the cellular level, including cancers such as lung cancer, breast cancer, prostate cancer, colon cancer, cervical cancer, esophageal cancer, bladder cancer, head and neck cancer, melanoma, low grade non-Hodgkin's Lymphoma, intermediate grade non-Hodgkin's Lymphoma, follicular lymphoma, large cell lymphoma, B-cell lymphoma, T-cell lymphoma, Mantle cell lymphoma, Burkitt's lymphoma, NK cell lymphoma, and acute lymphoblastic lymphoma. [0018] In some embodiments, additional steps can be employed in the present methods, including an initial step of reducing glucose ingestion in a subject prior to administering (and/or during administration of) the glucose-anti-neoplastic agent conjugate. Typically, this can be accomplished by withholding carbohydrate consumption for a period of up to 12-48 hours prior to administration of the conjugate. In another embodiment, the patient is administered an oral hypoglycemic agent prior to or contemporaneously with administration of the conjugate. Suitable oral hypoglycemic agents include but are not limited to metmorphin (Tolbutamide) and sulfonylurea (Glipizide). Also, a patient can be administered a high fat meal prior to administration, as free fatty acids block the uptake of glucose in the heart, and so can be used to prevent normal tissues from up-taking a conjugate of the invention. [0019] In a related aspect, the present invention provides methods for treating pre-cancer cells in a subject, comprising administering to the subject an effective amount of a glucose-anti-neoplastic agent conjugate. In one embodiment, the method is applied to the treatment of benign prostatic hypertrophy. [0020] In another related aspect, the present invention provides a method for enhanced delivery of an anti-neoplastic agent into cancer cells. BRIEF DESCRIPTION OF THE DRAWINGS Continue reading about Compositions and methods for treating cancer... Full patent description for Compositions and methods for treating cancer Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Compositions and methods for treating cancer patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Compositions and methods for treating cancer or other areas of interest. ### Previous Patent Application: Pyrrolidine derivatives for use in treating heaptitis c virus infection Next Patent Application: Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Compositions and methods for treating cancer patent info. IP-related news and info Results in 0.39861 seconds Other interesting Feshpatents.com categories: Daimler Chrysler , DirecTV , Exxonmobil Chemical Company , Goodyear , Intel , Kyocera Wireless , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
